• myStoria

  Participated · Seed · Mar 2026

  myStoria offers a patient-facing tool to centralise health history, symptom tracking and appointment preparation across fragmented care systems. The company is expanding its remit beyond fertility into PCOS, endometriosis and perimenopause. It plans to launch a mobile app with a freemium model to reach users directly. myStoria recently raised $1.625M in a seed round led by Graphite Ventures to fund those initiatives. The founder, Jessica Chalk, positions the product as the missing patient-facing layer in care. The company is based in Canada. The article did not disclose revenue, user metrics, valuation or prior funding rounds.

• Rithmik Solutions

  Participated · Equity · Mar 2024

  Rithmik Solutions develops an artificial-intelligence platform that ingests high-resolution data from mixed mobile mining fleets and converts it into actionable guidance for operations and maintenance teams. Its analytics go beyond predictive maintenance, enabling mines to detect issues earlier, improve equipment reliability, and increase production efficiency while reducing environmental impact. The software is fully OEM-agnostic, supporting all major mining equipment brands and addressing customers’ need for interoperable, site-wide solutions. Headquartered in Montréal, the company positions itself as a key enabler of smart, sustainable mining by aligning operational and maintenance priorities around data-driven insights. With fresh Series A funding, Rithmik plans to accelerate global expansion, broaden its product suite, and integrate into additional digital mining ecosystems. Financial or user metrics were not disclosed in the article.

• Noa Therapeutics

  Participated · Seed · Mar 2024

  Noa Therapeutics, founded in 2022 and based in Toronto, uses a computer-assisted drug discovery engine to identify multimodal therapeutic compounds for immune diseases. The pre-clinical startup is developing a portfolio of non-steroidal compounds that target immune modulation, barrier restoration, and microbiome modulation. Its lead program is directed at atopic dermatitis, and the company is also advancing work aimed at barrier-dysfunction inflammatory diseases such as ulcerative colitis and inflammatory bowel disease. Noa is a resident company of Johnson & Johnson’s JLABS Toronto within the MaRS Discovery District. The company was co-founded by CEO Carla Spina and CSO Serena Mandla and has announced a board that includes Maura Campbell and François Ravenelle. The new funding will support advancing the lead candidate and the hit-to-lead phase to optimize promising molecules into potential drugs.

• Tenomix

  Participated · Seed · Mar 2024

  Tenomix has developed a benchtop, printer-sized robotics system that uses ultrasound and artificial intelligence to automate the manual lymph node screening process used in colorectal cancer staging. The system is intended to reduce missed cancerous lymph nodes that can lead to improper staging and treatment. The device is currently undergoing validation in hospitals across the U.S. and Canada. Tenomix envisions the technology as a versatile platform with scalable software to support the pathology workflow. The company closed a $2 million all‑Canadian seed round to advance development and commercialization. Leadership says the funding and local ecosystem support will help the company build a profitable business and give pathology staff better tools to improve patient care.

• iosil Energy

  Participated · Equity · Mar 2010

  Iosil Energy Corporation is a producer of high-purity solar-grade polysilicon for the photovoltaic industry. The company is Albuquerque, New Mexico-based with R&D facilities located in the National Institute for Nanotechnology in Edmonton, Alberta. Founded in 2007, Iosil is preparing to move from R&D toward pilot manufacturing. It has secured the first close of a $13.5M equity financing round to advance those plans. The initial tranche will be used to specify and engineer a pilot plant facility in one of several locations under consideration. The full investment is intended to build out a pilot manufacturing plant and prepare the company for commercial introduction.

No current team members are available.